AC
SGMO

Allstate Corporation’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Allstate Corporation’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-12,326
Closed -$103K – 678
2019
Q4 		$103K Buy
+12,326
New +$113K ﹤0.01% 612

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Allstate Corporation's SGMO Position: Q1 2020 in Review

Allstate Corporation sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2020, closing a stake of 12,326 shares — an estimated $103K sold.

Allstate Corporation first reported a position in SGMO in Q4 2019 and held it in 1 quarter. The position peaked at $103K in Q4 2019. 190 funds tracked by Wall St. Rank hold SGMO as of Q1 2020.

  • Allstate Corporation reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2020 after selling out during the quarter.
  • Allstate Corporation sold 12,326 SANGAMO THERAPEUTICS INC shares in Q1 2020, an estimated $103K.
  • Allstate Corporation first reported a position in SANGAMO THERAPEUTICS INC in Q4 2019 and held it in 1 quarter.
  • Allstate Corporation's SANGAMO THERAPEUTICS INC position peaked at $103K in Q4 2019.
  • 190 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2020.

Based on Allstate Corporation's 13F filing for Q1 2020, filed 15 May 2020.